Medical Industry Feature

Guest: Dena Goffman, MD Dr. Dena Goffman believes that better maternal care requires a proactive, system-wide approach and is making her vision a reality at NewYork-Presbyterian. She focuses on implementing guidelines that standardize care across all of NewYork-Presbyterian’s hospitals. Dr. Goffman has also aided in FDA approval and adoption of a new, ingenious hemorrhage tool and embraced simulations to train and improve the skills of healthcare professionals throughout the labor and delivery process. Join health and science journalist Catherine Price as she speaks with Dr. Dena Goffman, Vice Chair for Quality and Patient Safety and the Associate Chief and Quality Officer for Obstetrics for NewYork-Presbyterian, about how her work has helped establish goals and quality standards for safer labor and delivery. © 2024 NewYork-Presbyterian

Guest: Michael Kaplitt, MD, PhD For the first time, Dr. Michael Kaplitt was able to perform a trial for a neurological gene therapy that was administered in a human patient to address damaged brain cells caused by Parkinson’s disease. This procedure used an adeno-associated virus to deliver a gene into the brain of a patient with Parkinson’s. The results were groundbreaking and paved new avenues for research in neurological gene therapy, such as preventative intervention. Join health and science journalist Catherine Price as she speaks with Dr. Michael Kaplitt, Executive Vice Chair of the Department of Neurological Surgery at NewYork-Presbyterian/Weill Cornell Medicine, as he discusses the story of his breakthrough and how he’s continuing to evolve the field of neurosurgery. © 2024 NewYork-Presbyterian

Guest: Pierre Elias, MD In this episode, you’ll gain insights into Dr. Elias’ innovative approach, integrating technology, data science, and medicine to develop algorithms that aim to enhance accuracy in predicting cardiovascular disease while allowing them to focus on providing personalized care to their patients. This could even help diagnose patients before symptoms occur. Join health and science journalist Catherine Price as she speaks with Dr. Pierre Elias, Medical Director of Artificial Intelligence at NewYork-Presbyterian, about the future of technology in medicine. © 2024 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Arnaud Bourdin, MD, PhD Since many severe asthma patients have been shown to have mucus plugs, it’s important to understand the role they plan in severe asthma. Join us as we discuss an exploratory study and the role of mucus plugging in severe asthma with Dr. Charles Turck and Professor Arnaud Bourdin. Professor Bourdin is the Head of Pulmonology at the Arnaud de Villeneuve Hospital in Montpellier, France. TEZSPIRE is a registered trademark of Amgen Inc. and AstraZeneca.©2024 Amgen and AstraZeneca. All rights reserved. US-83499 Last Updated 1/24

Guest: Christopher Petit, MD Pulmonary vein stenosis (PVS) is a rare and challenging heart condition, which narrows blood vessels around the lungs and typically impacts newborn children. Historically, the rates of survival have been low, but with Dr. Petit leading the development of innovative techniques and treatments, the trajectory of patients’ lives could positively change. Join health and science journalist Catherine Price and Dr. Christopher Petit, Co-Director of Children’s Heart Center at NewYork-Presbyterian Morgan Stanely Children’s Hospital and Division Chief of Pediatric Cardiology at Columbia University, to discuss breakthroughs and treatments that are making a big impact on pediatric survival rates. © 2024 NewYork-Presbyterian

Guest: Conor Liston, MD, PhD For patients diagnosed with depression for the first time the recommended course of treatment is the same; however, there’s a large patient population for whom these treatments won’t work. So it became increasingly important for Dr. Liston to map the brains of people suffering from major depression to see how it was impacting brain structures and symptoms. The research showed that certain networks expanded in the brains of patients who had depression and pushed into other networks. Learn more about identifying how these symptoms impact the patient’s brains, analyzing the best course for treatments, and how this research could be the key to effectively using transcranial magnetic stimulation to help patients with treatment-resistant depression. Join health and science journalist Catherine Price as she speaks with Dr. Conor Michael Liston, Psychiatrist at NewYork-Presbyterian/Weill Cornell Medicine, to discuss these approaches to help treatment-resistant depression. © 2024 NewYork-Presbyterian

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jamie Koprivnikar, MD Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health. REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.© 2024 Bristol-Myers Squibb Company2007-US-2300376 03/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jamie Koprivnikar, MD Patients with lower-risk myelodysplastic syndromes (MDS) lack treatment options, specifically in treating anemia. However, the FDA approval of Reblozyl (luspatercept-aamt) as a first-line therapy for treating anemia in ESA-naïve patients with lower-risk MDS presents an option for this patient population. Tune in to learn more about evaluating patients with MDS, the potential of Reblozyl, and where it fits into the treatment landscape with Dr. Charles Turck as he takes a deep dive with Dr. Jamie Koprivnikar, MD, Hematologist, Oncologist, at Hackensack Meridian Health. REBLOZYL® is a trademark of Celgene Corporation, a Bristol Myers Squibb company.REBLOZYL® is licensed from Merck & Co. Inc., Rahway, NJ, USA and its affiliates.© 2024 Bristol-Myers Squibb Company2007-US-2300376 03/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Arnaud Bourdin, MD, PhD It’s only been a recent discovery that mucus plugging may be present and persistent in chronic severe asthma.1 In fact, studies have shown that mucus plugs may drive some lung function deficits in severe asthma.1 Given this recent finding, Dr Charles Turck speaks with Professor Arnaud Bourdin about the clinical significance and pathogenesis of mucus plugging in severe asthma. Professor Bourdin is Head of Pulmonology at Arnaud de Villeneuve Hospital in Montpellier, France. Reference: Dunican EM, Watchorn DC, Fahy JV. Ann Am Thorac Soc. 2018;15(Suppl 3):S184-S191. doi:10.1513/AnnalsATS.201807-485AW ©2024 Amgen and AstraZeneca. All rights reserved. US-86740 Last Updated 3/24

Host: Jennifer Caudle, DO Guest: Victoria A. Statler, MD, MSc Test-confirmed influenza outcomes provide a specific measure of influenza vaccine effectiveness (VE) and has helped to illustrate the potential benefit of cell-based versus egg-based vaccines.1 So what data support improved VE from cell-based flu vaccines versus egg-based vaccines? To learn more, join Dr. Jennifer Caudle as she speaks with Dr. Victoria A. Statler, Associate Professor of Pediatrics at the University of Louisville and the Director of the Pediatric Transplant and Immunocompromised Host service at Norton Children’s Hospital. Reference: Stein AN, Mills C, McGovern, et al. Superior effectiveness of cell-based versus egg-based quadrivalent influenza vaccines against test-confirmed influenza over three consecutive seasons in the United States. Paper presented at: The Ninth European Scientific Working Group Influenza (ESWI) Influenza Conference; September 17-20, 2023: Valencia, Spain. USA-QIVc-23-0119 01/24

Guest: Stephen I. Pelton, MD Influenza disproportionately affects adults 65 and older as a result of increased frequency of comorbidities and immunosenescence.1,2 And it’s also linked to neurologic, cardiovascular, and respiratory complications in high-risk groups, while potentially exacerbating underlying chronic medical conditions.1,2 So how can adjuvanted vaccines help patients who are affected? Dive in to learn more with Dr. Stephen Pelton, Professor of Pediatrics at Boston University Chobanian and Avedisian School of Medicine. References: Pelton SI, Nguyen VH, Mould-Quevedo JF. The value of influenza vaccination in the older adult population. A stochastic model estimation of the benefit of vaccination to prevent the severe outcomes in the U.S. Poster presented at: IDWeek 2023; October 11-15; Boston, MA. Pelton SI, Mould-Quevedo JF, Nguyen VH. The impact of adjuvanted influenza vaccine on disease severity in the US: a stochastic model. Vaccines. 2023; 11(10):1525. https://doi.org/10.3390/vaccines11101525 USA-FLUD-23-0011 12/23

Guess what? The CDC's Advisory Committee on Immunization Practices had a unanimous vote in favor of a preferential recommendation of vaccines for the cool adults who are 65 and older—one of these options is adjuvanted influenza vaccines.1 Talk about a milestone in the world of public health! Now the burning question is why on earth did they decide on adjuvant vaccines? Let's unravel this immunization mystery together, shall we? Reference: Grohskopf LA, Blanton LH, Ferdinands JM, Chung JR, Broder KR, Talbot HK, Morgan RL, Fry AM. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 influenza season. MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1 USA-CRP-23-0037 12/23

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Wendy Wright, DNP Guest: Elias Chahine, PharmD, FCCP, FASCP While the flu may seem benign to some, it may result in up to 710,000 hospitalizations and up to 52,000 deaths every year.1 So how are current and concerning trends in declining flu vaccinations being addressed? To hear the latest updates and recommendations, join Dr. Charles Turck as he speaks with Dr. Wendy Wright, Owner and Family Nurse Practitioner at Wright & Associates Family Healthcare in New Hampshire, and Dr. Elias Chahine, Professor of Pharmacy Practice at Palm Beach Atlantic University in West Palm Beach, Florida and Clinical Pharmacy Specialist at Wellington Regional Medical Center. Reference: Disease Burden of Influenza. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/about/burden/index.html. Updated October 4, 2022. Accessed November 28, 2023. USA-CRP-23-0043 01/24

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Brian Iacoviello, MD Since the thinking part of depression may involve getting stuck on the sad or the negative thoughts, there is a need to focus on not just cognitive control for information but for emotional information processing.1 And that fits with the picture that we get from brain imaging research that shows hyperactivity in the emotion-processing region of the brain and a quieting-down of the cognitive control region of the brain when people are depressed.1 To take a deep dive, join Dr. Brian Iacoviello, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai in New York City. Reference Iacoviello BM, Wu G, Alvarez E, et al. Cognitive-emotional training as an intervention for major depressive disorder. Depress Anxiety. 2014;31(8):699-706. January 2024 US.UNB.X.23.00076

Guest: Aderonke Pederson, MD Major depressive disorder is a mental health condition that affects millions of Americans,1 and for the past several decades, treatment has consisted mainly of antidepressant therapy and psychotherapy.2,3 However, many patients still don't achieve their treatment goals and there are many potential barriers to accessing treatment. Learn more about these unmet needs in major depressive disorder care that underscore the importance of finding new treatment approaches with Dr. Aderonke Pederson, Assistant Professor of Psychiatry at Harvard Medical School. References: National Institute of Mental Health. Major depression. National Institute of Mental Health. July 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/statistics/major-depression National Institute of Mental Health. Depression. National Institute of Mental Health. September 2023. Accessed November 10, 2023. https://www.nimh.nih.gov/health/topics/depression American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder, 3rd ed. American Psychiatric Association Publishing. 2010. Accessed November 10, 2023. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf January 2024 US.UNB.X.23.00150

Host: Jennifer Caudle, DO Guest: Manpreet Mundi, MD Enteral nutrition intolerance is quite prevalent as it can be seen in up to 40 percent of patients who are tube fed. Due to the significant consequences of intolerance, there’s an urgency to manage patients symptoms, and one option that’s been shown to help is peptide-based tube feeding formulas. Joining Dr. Jennifer Caudle to talk about the management of enteral feeding intolerance with peptide-based tube feeding formulas is Dr. Manpreet Mundi, Professor of Medicine in the Department of Endocrinology at the Mayo Clinic College of Medicine and Science in Rochester, Minnesota. All trademarks are owned by Société des Produits Nestlé S.A., Vevey, Switzerland. ©2023 Nestlé

Guest: Richard Lafayette, MD, FACP Insights into the complement system are critical to our understanding of the pathogenesis of immunoglobin A (IgA) nephropathy.1 That’s why Dr. Richard Lafayette is here to share what we currently know about the complement system and its role in IgA nephropathy. Dr. Lafayette is a nephrologist at Stanford University Medical Center in California. References: Medjeral-Thomas NR, O'Shaughnessy MM. Adv Chronic Kidney Dis. 2020 Mar;27(2):111-119. doi: 10.1053/j.ackd.2019.12.004 319698 12/23

Guest: Jai Radhakrishnan, MD The most widely accepted mechanism for the pathogenesis of immunoglobin A (IgA) nephropathy is referred to as the “four-hit model,” which is a sequence of four events that can occur.1-3 Here to break down each of those four stages is Dr. Jai Radhakrishnan, a nephrologist at Columbia University Medical Center in New York. References: Knoppova B, Reily C, King RG, et al. J Clin Med. 2021;10(19):4501. doi:10.3390/jcm10194501 Maillard N, Wyatt RJ, Julian BA, et al. J Am Soc Nephrol. 2015;26(7):1503-1512. doi:10.1681/ASN.2014101000 Chang S, Li X-K. Front Med (Lausanne). 2020;7:92. doi:10.3389/fmed.2020.00092 319698 12/23

Guest: Mark Haas, MD Kidney biopsy is the gold standard for the diagnosis of immunoglobin A (IgA) nephropathy and complement 3 glomerulopathy (C3G),1,2 and the accurate interpretation of kidney biopsy findings is important not only for diagnosis but also guiding clinical management of these conditions. Learn more about what the diagnostic process and findings for IgA nephropathy and C3G look like with Dr Mark Haas, a renal pathologist at Cedars-Sinai Medical Center in Los Angeles. References: Mehdi A, Taliercio JJ. Cleve Clin J Med. 2023;90(6)(suppl 1):e1-e4. doi:10.3949/ccjm.90.e-s1.02 Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Nephron. 2020;144(6):272-280. doi:10.1159/000507254 319698 12/23

Guest: Michael Farbaniec, MD Guest: Emma Hegwood, DO Guest: Britt Heller, MSN, RN Explore the acquisition pathways and learn key strategies for implementing LEQVIO® (inclisiran) into your practice with Dr Michael Farbaniec, Lipid Clinic Director in Pennsylvania, Dr Emma Hegwood, a cardiology fellow with Dr Farbaniec in the Clinical World of Cardiology and also a LEQVIO patient, and Care Coordinator and Registered Nurse Brittany Heller. Dr Farbaniec, Dr Hegwood, and Ms Heller have all been compensated for their time.